Modified Duhuo Jisheng Decoction （独活寄生汤） as an Adjunct to Chemotherapy for Multiple Myeloma with Kidney Deficiency and Blood Stasis Syndrome： A Randomized Controlled Trial
10.13288/j.11-2166/r.2026.22.010
- VernacularTitle:独活寄生汤加减辅助化疗方案治疗肾虚血瘀型多发性骨髓瘤的随机对照试验
- Author:
Wenjin QIANG
1
;
Jingyi LIU
1
;
Wanyi SUN
1
;
Yun BAI
1
;
Xia ZHOU
1
;
Xuemei SUN
1
;
Pengjun JIANG
1
;
Xingbin DAI
1
Author Information
1. The First Clinical Medical College，Nanjing University of Chinese Medicine，Nanjing，210023
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
kidney deficiency and blood stasis;
bone pain;
quality of life;
Duhuo Jisheng Decoction （独活寄生汤）
- From:
Journal of Traditional Chinese Medicine
2026;67(22):2420-2427
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy and safety of modified Duhuo Jisheng Decoction （独活寄生汤， DJD） as an adjuvant to chemotherapy in the treatment of multiple myeloma （MM） of kidney deficiency and blood stasis syndrome. MethodsA total of 65 patients with MM of kidney deficiency and blood stasis syndrome were randomly divided into a treatment group （32 cases） and a control group （33 cases）. The control group received a standardized chemotherapy regimen， while the treatment group additionally received modified DJD. Both groups received 28 days as one course of treatment for a total of three courses. The primary outcome was the total effective rate of traditional Chinese medicine （TCM） syndromes. The total TCM syndrome score， Numerical Rating Scale （NRS） score for bone pain， Karnofsky Performance Status （KPS） score， and laboratory indicators including hemoglobin（Hb）， β2-microglobulin（β2-MG）， and serum creatinine（SCr））， were compared between the two groups before and after treatment. After treatment， the clinical efficacy according to western medicine criteria and the incidence of adverse reactions were also evaluated. ResultsThe total effective rate of TCM syndrome was 93.75% （30/32） in the treatment group， significantly higher than 75.76% （25/33） in the control group （P＜0.05）. The total clinical effective rate according to western medicine criteria was 87.50% （28/32） in the treatment group and 78.79% （26/33） in the control group， with no statistically significant difference between the two groups （P＞0.05）. After treatment， the TCM syndrome scores and NRS scores significantly decreased， while KFS scores increased in both groups （P＜0.01）. The treatment group had significantly lower total TCM syndrome scores and NRS scores and higher KPS score than the control group （P＜0.05）. The treatment group showed an increase in Hb levels and decreases in β2-MG and SCr levels， whereas the control group showed only an increase in Hb level （P＜0.05）. The SCr level in the treatment group was lower than that in the control group （P＜0.05）. The incidence of drug-related peripheral neuropathy was 25.00% （8/32） in the treatment group， significantly lower than 51.52% （17/33） in the control group （P＜0.05）. ConclusionModified DJD as an adjunct to chemotherapy for MM with kidney deficiency and blood stasis syndrome can significantly reduce clinical symptoms， relieve bone pain， improve quality of life， and reduce the incidence of drug-related peripheral neuropathy. It may also exert a protective effect against MM-related renal impairment and demonstrates a favorable safety profile.
